Sabesp SBS 深 沪
已收盘 08-21 16:00:00 美东时间
4.61
+0.150
+3.36%
华盛通- 最 高4.64
- 今 开4.49
- 成交量 1329.86万股
- 最 低 4.49
- 昨 收 4.46
- 总市值 162.12亿
- 52周最高 7.157
- 市盈率 静 10.43
- 换手率 0.38%
- 52周最低 4.1456
- 委 比 -0.29%
- 总股本 35.17亿
- 历史最高 17.0432
- 量 比 1.26
- 振 幅 3.36%
- 历史最低 -0.0933
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Companhia de Saneamento Basico do Estado de Sao Paulo SABESP (SBSP3) Receives a Buy from Jefferies
In a report released yesterday, Alejandro Demichelis from Jefferies maintained ...
08-14 11:15
AI power demand: Utilities cashing in on data center expansion
Investors Should Know: AI data center expansion is creating a surge in power demand. Utilities and independent power producers are building long-term revenue visibility through large-scale electricity...
06-30 02:24
美股盘后 | Ares Management Corporation涨5.75%，齐默巴奥米特涨2.31%
Ares Management Corporation涨5.75%；齐默巴奥米特涨2.31%；Krystal Biotech, Inc.涨2.28%
06-19 06:10
美股盘后 | CRH水泥涨4.88%，Guardant Health涨3.79%
CRH水泥涨4.88%；Guardant Health涨3.79%；Samsara涨3.48%
06-18 06:10
Seeking Alpha量化评分揭晓：当前十大最具投资价值外资公用事业股
Seeking Alpha的量化系统每月对全球数千只股票进行评分，综合考量估值、增长、盈利能力和市场情绪等因素。对于寻求防御性配置和稳定现金流的投资者而言...
05-08 22:33
Sabesp Posts Higher Assets in First-Quarter 2026 Financial Report
Companhia De Saneamento ( ($SBS) ) just unveiled an announcement. Sabesp report...
05-08 19:56
巴西基建热潮推动下，激励型债券发行首次超越普通债券
根据Galapagos Capital分析的数据，2026年第一季度，巴西通过发行激励型基础设施债券的融资额达到440亿雷亚尔，首次超越同期普通债券的发行量...
04-28 03:37
Central Puerto, Iberdrola lead utilities quant picks ahead of Q1earnings
The S&P 500’s Utilities Sector (XLU) gained about 6.3% during the first quarter, compared with a nearly 4.8% decline in the broader market. According to the latest FactSet data, the utilities sector i...
04-07 23:13
Sabesp Proposes 1-for-5 Stock Split Ahead of April 28 Shareholder Vote
An announcement from Companhia De Saneamento ( ($SBS) ) is now available. On Ma...
03-30 22:14
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
